New Board of Directors - AMGQ President outlines her vision for a more concerted approach to the challenges of caring for Québec's aging population Français
MONTREAL, June 9, 2025 /CNW/ - At its annual general meeting, the Association des médecins gériatres du Québec (Québec's association of geriatric physicians, known by its French abbreviation AMGQ) has acclaimed Dr. Julia Chabot to a two-year term as Chair of the Board of Directors and Association President.
Dr. Chabot assumes her duties with a clear vision of the future of geriatrics in Québec and, to that end, is advancing the idea of a more concerted approach through the creation of the Programme québécois de gériatrie (Québec geriatrics program, or PQG).
"With the Québec population aging at an increasing pace, it is more vital than ever that we adapt our healthcare environment and emphasize prevention so as to meet the growing needs of the elderly, no matter where they live or receive care," Dr. Chabot said. "In the AMGQ's view, developing a PQG will enable a better response to that situation. We would like the Health and Social Service Ministry and other partners to make vital contributions to our thinking process as we work to develop this program."
For example, the responding geriatrician project, which was recently the subject of an agreement, perfectly captures the essence of PQG. "Making sure that more people have access to geriatric expertise is a key priority for us," Dr. Chabot continued. "For me and the entire AMGQ membership, this agreement is the culmination of months of hard work, and we are delighted with the result. We are eager to get down to work to ensure its successful implementation across the network, first through pilot projects and then more widely," she concluded.
A renewed Board of Directors
In addition to the appointment of Dr. Chabot as Chair, Dr. Chantal Paré has been named Vice-Chair of the Association. The Board of Directors consists of the following officers:
Dr. Julia Chabot, Chair
Dr. Chantal Paré, Vice-Chair
Dr. Thiên Tuong Minh Vu, Treasurer
Dr. Michael Stiffel, Secretary
Dr. Julie Kirouac Laplante, Member Responsible for Continuous Professional Development
Dr. Alex Halme, Advisor
Dr. Carolane Rioux, Advisor
AMGQ outgoing Chair and President Dr. Jacques Morin concludes his term of office with a sense of having accomplished his duties, and sees the future in a positive light. "I have no doubt that, with such a strong and committed Board of Directors, the AMGQ is well positioned for the future. I take this opportunity to thank all of our members for the trust they have placed in me these past few years, and for their dedication to delivering quality care to Quebecers," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
Cision Canada
11 hours ago
- Cision Canada
Ambassadors Accelerate CarePatrol's AlignedCare™ Program
Beta testing begins for proprietary value-based care model driven by advisor insights OTTAWA, Ontario, June 9, 2025 /CNW/ -- CarePatrol, a leading senior care solutions franchise with more than 200 locations open across 40 states and Canada, is advancing its proprietary AlignedCare™ Value-Based Care (VBC) Certification Program with the selection of its first Ambassador team. The select group of experienced advisors will act as early adopters, leading beta testing and shaping the future for value-based care integration within senior care advisory services. The AlignedCare Program represents a transformative step in how care solutions are guided and recommended. Advisors who complete the certification will be qualified to support families using an evidence-informed model based on outcomes, social determinants of health, and care collaboration. Built on value-based care principles informed by the 8 Dimensions of Wellness, the program enables higher levels of client precision and personalization, while also expanding value-based care partnership networks. Throughout the beta phase, AlignedCare Ambassadors will be applying the model within their current practices and providing critical feedback on assessment tools, strategic workflows, and outcomes tracking. Insights provided and gained during this phase will assist in system-wide implementation. "We're thrilled with the early momentum of the AlignedCare Program and the enthusiasm from our Ambassador team," said Becky Bongiovanni, co-founder and brand president of CarePatrol. "Our advisors are stepping into a leadership role that goes far beyond traditional care advisory. By aligning every recommendation with value-based care principles, we are building a more complete, measurable, and compassionate model for senior care." Each AlignedCare Ambassador plays a vital role in strengthening CarePatrol's mission to strengthen senior care advisory services through professional development, collaboration, and meaningful community impact. This next phase of the initiative builds on CarePatrol's legacy of innovation, using evidence-informed practices to deliver personalized, outcome-focused advisory solutions. A full system-wide rollout of the AlignedCare™ Certification Program is anticipated later this year. About CarePatrol CarePatrol is the nation's largest senior care solutions franchise in the United States. With more than 225 locations sold across 40 states and Canada, local senior advisors provide a no-cost service in helping families find quality, top-rated independent living, assisted living, memory care, long-term care, and home care. Founded in 1993, CarePatrol began franchising in 2009 and is now part of the Best Life Brands family, with private equity backing by The Riverside Company. CarePatrol is proud to have earned the Franchisee Satisfaction Award from Franchise Business Review for 14 years in a row, including its induction into the Hall of Fame in 2024, and has earned placement on the Entrepreneur Franchise 500 list. For more information, visit
Cision Canada
11 hours ago
- Cision Canada
Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care Français
TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healthcare around the globe. The company is building on this momentum, leveraging next-gen technology and AI, to turn breakthrough science into reality for patients. I feel privileged to be back home in Canada working with our talented teams; I'm confident that their patient-focused approach will deliver new solutions that will continue to benefit Canadian patients." Guy brings over two decades of pharmaceutical industry experience, including 13 years with Sanofi in global, US, and Canadian leadership roles, most recently as the Immunology Franchise Head in Canada. His prior positions within Sanofi include International Strategic Marketing Director based in the Czech Republic, Respiratory Global Brand Lead based in the US, and Regional Business Director in the US affiliate. A Canadian citizen, Guy holds a in Applied Chemistry & Biology from Toronto Metropolitan University, an in Biomedical Sciences from the University of Bradford (UK), and an MBA from Rutgers University (USA). With over 2,000 employees across the country, Sanofi's operations in Canada include R&D, Commercial, the country's largest biomanufacturing facility, and an AI Centre of Excellence. The company is uniquely positioned to deliver across the full life sciences value chain within Canada. As Country Lead, Guy will chair the Canada Country Council, which includes: About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. In Canada, we employ over 2,000 people and invest 20% of our revenue annually in biopharma research, representing $1.2 billion CAD in R&D over the last decade, creating jobs, business, and opportunity throughout the country. We are the largest biomanufacturing facility in Canada and are on track to deliver over $2 billion in new infrastructure investments by 2028, including two new vaccine manufacturing facilities at our Toronto Campus. For more than 110 years, we have been working in collaborative partnerships with a vast network of healthcare stakeholders and are committed to creating a healthier future in Canada.
